Related Experiment Videos
[Allergic bronchopulmonary aspergillosis (ABPA)]
1Deutsche Hochgebirgsklinik Davos-Wolfgang, Switzerland. guenter.menz@hgk.ch
Pneumologie (Stuttgart, Germany)
|July 16, 2003
Summary
Allergic bronchopulmonary aspergillosis (ABPA) diagnosis is complex. New recombinant allergens improve early and precise detection, aiding timely treatment and preventing severe outcomes.
Area of Science:
- Pulmonology
- Allergology
- Mycology
Context:
- Allergic bronchopulmonary aspergillosis (ABPA) is a common human fungal infection.
- Current diagnostic criteria for ABPA vary across its five clinical stages, complicating accurate diagnosis.
- Distinguishing ABPA remission from allergic asthma with Aspergillus fumigatus sensitization is challenging.
Purpose:
- To describe the potentials and limitations of current routine diagnostic procedures for ABPA.
- To highlight the advancement in diagnostic accuracy using recombinant allergens.
- To outline therapeutic strategies for ABPA, including corticosteroids and antimycotics.
Summary:
- ABPA diagnosis relies on defined criteria, but variability across stages complicates identification.
- Traditional diagnostic methods using crude allergen extracts suffer from batch variation and lack standardization.
- Recombinant allergens of A. fumigatus offer improved accuracy for early and precise ABPA diagnosis, particularly in vitro.
- A panel of recombinant allergens is now available for routine use in the CAP-System assay.
- Therapeutic management involves glucocorticosteroids for exacerbations and long-term control, with consideration for antimycotic drugs.
Impact:
- Early and precise ABPA diagnosis prevents progression to severe lung damage.
- Standardized recombinant allergens enhance diagnostic reliability and reproducibility.
- Improved diagnostic tools facilitate timely and appropriate therapeutic interventions for ABPA patients.